TELECOPIER TRANSMISSION

BRISTOL-MYERS SQUIBB COMPANY
Legal Division
P.O. Box 5100
5 Research Parkway
Wallingford, CT 06492-7660

TO: USPTO (Alexandria, VA)
TELECOPIER NO: 9-1-571-273-0546
FROM: James Epperson
TELECOPIER NO: 203-677-6900
TOTAL NUMBER OF PAGES INCLUDING THIS ONE: 5
DATE: 9/1/05

IN RE APPLICATION OF
CHATURVEDULA, ET AL
APPLICATION NO: 10/813,870
FILED: MARCH 30, 2004
FOR: AMIDOHETEROCYCLES AS MODULATORS OF THE MELANOCORTIN-4 RECEPTOR
DOCKET: CT-2773 NP

EXAMINER: ZINNA NORTHINGTON DAVIS
ART UNIT: 1625

SIRS:

Enclosed with this facsimile transmission sheet is the following document:

(1) Listing of claims in response to Office Action dated 8/29/2005 (Notice of Non-Compliant Amendment) having a due date for reply of 9/29/2005.

James Epperson
Agent for Applicant
Reg. No. 52,867
Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
203-677-6974

Amendments to the Claims

1. (original) A compound of Formula I



I

wherein:

A is hydrogen, C_{1-4}alkyl, C_{1-4}aminoalkyl, or a heterocycle selected from the group consisting of  ,



W is NR^3, O, or S;

R^1 is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkyloxy, cyano, trifluoromethyl, and alkoxycarbonyl;

R^2 is C_{1-6}alkyl or C_{3-7}cycloalkyl;

R^3 is hydrogen or C_{1-6}alkyl;

m is 0, 1, 2, or 3;

n is 1 or 2;

X is CO or SO_2;

B is selected from C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylmethyl; C_{1-3}methoxyalkyl, and C_{1-3}phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl,

PAGE 2/5 * RCVD AT 9/1/2005 1:14:01 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/32 * DNIS:2730546 * CSID:2036776900 * DURATION (mm-ss):00-58

oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl, benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxyl, trifluoromethyl, cyano, and $-N(R^3)_2$;

or a pharmaceutically acceptable salt or solvate.

2. (Currently amended) A compound of ~~claim 1~~ the following formula where the carbon marked with an asterisk is of the (R) stereochemistry.



wherein:

A is hydrogen, C_{1-4}alkyl, C_{1-6}aminoalkyl, or a heterocycle selected from the group consisting of 



W is NR^3, O, or S;

R^1 is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkyloxy, cyano, trifluoromethyl, and alkoxycarbonyl;

R^2 is C_{1-6}alkyl or C_{3-7}cycloalkyl;

R^3 is hydrogen or C_{1-6}alkyl;

m is 0, 1, 2, or 3;

n is 1 or 2;

PAGE 3/5 * RCVD AT 9/1/2005 1:14:01 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/32 * DNIS:2730546 * CSID:2036776900 * DURATION (mm-ss):00-58

X is CO or SO_2;

B is selected from C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylmethyl; C_{1-3}methoxyalkyl, and C_{1-3}phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl, benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxyl, trifluoromethyl, cyano, and $-N(R^3)_2$;

or a pharmaceutically acceptable salt or solvate.

3. (original) A compound of claim 1 where A is C_{1-4}aminoalkyl, or a heterocycle selected from  , , and  .

4. (original) A compound of claim 1 where m is 1 and R^1 is phenyl substituted with 1-2 substituents selected from halo, alkyl, alkyloxy, cyano, carboalkoxy.

5. (original) A compound of claim 1 where X is CO and B is selected from C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylmethyl, C_{1-3}methoxyalkyl, and C_{1-3}phenoxyalkyl or is selected from phenyl, pyrazinyl, furanyl, isoxazolyl, and benzthienyl, moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and $-N(R^3)_2$.

6. (original) A compound of claim 1 where n is 1.

7. (currently amended) The compound of claim ~~7~~ 6: N-[1-[(2R)-3-(4-Chlorophenyl)-2-[[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-azetidinyl]-N-cyclohexyl-3-methyl-butanamide.

8. (original) A compound of claim 1 where n is 2.

9. (cancelled)

10. (currently amended) A compound of claim ~~9~~ 8 selected from the following group:

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

PAGE 4/5 * RCVD AT 9/1/2005 1:14:01 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/32 * DNIS:2730546 * CSID:2036776900 * DURATION (mm-ss):00-58

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

(2S)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(1-oxopentyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(2-furanylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

N-[1-[(2R)-3-(4-Chlorophenyl)-2-[(3S)-[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-pyrrolidinyl]-N-cyclohexyl-3-methyl-butanamide; and

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(methylsulfonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide.

11. (original) A pharmaceutical composition comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

12. (cancelled)

PAGE 5/5 * RCVD AT 9/1/2005 1:14:01 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/32 * DNIS:2730546 * CSID:2036776900 * DURATION (mm-ss):00-58